Search

everythinglearnresearchcommunity

for

Search:↓

Hormone therapy in transgender women can affect hair growth and acne, and there are specific skin issues related to gender-affirming surgery, but more research is needed on their dermatological health.

ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.

Glucocorticoids and sex hormones affect skin health, with potential for targeted treatments to minimize side effects and treat skin conditions.

The commentary suggests that certain hair and skin care products may be linked to frontal fibrosing alopecia, but not sunscreens, and calls for more thorough research on the causes.

Melasma is a skin condition linked to female hormones, genetics, UV exposure, and certain medications, but not to pituitary, adrenal, or thyroid diseases.

Nutraceuticals that promote hair growth do not reduce tamoxifen's effectiveness in breast cancer treatment.

Dihydrotestosterone makes arteries stiffer in female mice by reducing estrogen receptor expression.

Estrogens and progesterone are key in regulating melasma pigmentation.

Finasteride and minoxidil are effective, low-risk treatments for male hair loss, and patient education on these therapies is important.

Gender affects hair and scalp characteristics, with differences in hormone responses, graying patterns, and trace metals.

Androgens and other hormones affect hair growth and skin conditions like acne.

Combination of 0.25% finasteride and 3% minoxidil works better than just 3% minoxidil for increasing hair thickness in women.

Blood tests can detect ovarian Leydig cell tumors when scans don't, and surgery can confirm and treat these tumors.

Tamoxifen can cause total hair loss but its benefits outweigh this side effect.

Removing both ovaries may better treat increased male hormone levels and related symptoms in postmenopausal women when hormone therapy doesn't work.

Tinea capitis in adults, especially postmenopausal Black women, needs prompt treatment with oral antifungals to avoid scarring.

The treatment helped reduce symptoms and stabilize the hairline in most patients with Frontal Fibrosing Alopecia, but hair regrowth was limited.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

"Male-pattern" hair loss is common in women, especially after menopause, and doesn't always mean there's a problem with hormone balance.

Menopause-related hormonal changes affect hair but are not the only cause of hair changes in middle-aged women.

After chemotherapy for a gestational trophoblastic tumor, normal pregnancy rates are possible, but there's a slightly higher risk of the tumor reoccurring in future pregnancies.

The conclusion is that thorough investigation of hypertension and hormonal dysfunctions is important, and there may be a link between these conditions and cancer.

The document concludes that women's health needs a holistic approach, considering all life stages, promoting lifestyle changes, regular exercise, proper diet, and vaccinations, with health professionals playing a key role in education and guidance.

The document concludes that hair loss in women can be treated with topical treatments or hormone therapy depending on the cause.

SHBG may be a useful early indicator and treatment target for PCOS.

Transgender women can develop feminine traits and improve their quality of life through hormone therapy and surgery, but results vary and access to surgery can be limited.

Sex steroids, especially progesterone, can slow down the growth of mouse melanoma cells.

A man with a rare adrenal cancer showed unusual symptoms and died four months after diagnosis.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Testosterone therapy may slightly increase sexual desire in women with HSDD but lacks broad recommendation due to safety concerns and limited approval.